Market Research Logo

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Pipeline Review, H2 2018

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Pipeline Review, H2 2018

Summary

According to the recently published report '5-Hydroxytryptamine Receptor 6 - Pipeline Review, H2 2018'; 5-Hydroxytryptami


Introduction
Global Markets Direct Report Coverage
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Overview
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Companies Involved in Therapeutics Development
Acorda Therapeutics Inc
Adamed Sp z oo
Avineuro Pharmaceuticals Inc
Celon Pharma SA
H. Lundbeck AS
Reviva Pharmaceuticals Inc
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Drug Profiles
ADN-1184 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADN-2013 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADN-3662 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AV-3208 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVN-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVN-211 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVN-3205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVN-322 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVN-492 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HEC-30654AcOH - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
landipirdine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LuAF-35700 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RP-5063 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize 5-HT 6 and 5-HT2A for Behavioral and Psychological Symptoms of Dementia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize 5-HT6 for Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize 5-HT6 Receptor for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SUVN-502 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Dormant Products
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Discontinued Products
5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Product Development Milestones
Featured News & Press Releases
Apr 10, 2018: Reviva Pharmaceuticals Receives FDA Orphan Designation for RP5063 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Jan 10, 2018: Avineuro Pharmaceuticals Reported Phase Ib Trial Results of AVN-101
Nov 13, 2017: Suven Life sciences announces presentation on its cognitive disorders drug candidate SUVN-502 at Neuroscience 2017 at Washington DC
Oct 17, 2017: Reviva Pharmaceuticals Announces Successful Completion of Pre-IND Meeting With FDA on RP5063 for the Treatment of Pulmonary Arterial Hypertension
Nov 17, 2016: Reviva Pharmaceuticals Receives FDA Orphan Designation for Pulmonary Arterial Hypertension (PAH)
May 19, 2016: Reviva Pharmaceuticals Presented RP5063 Preclinical Efficacy Results for Pulmonary Arterial Hypertension at the American Thoracic Society Conference 2016
Mar 11, 2016: Lundbeck starts clinical phase III program with Lu AF35700 in patients with treatment resistant schizophrenia
Dec 07, 2015: Suven Initiates Phase 2A trial of SUVN-502 in USA in Alzheimer’s Disease
Oct 22, 2015: Reviva Pharmaceuticals Reports RP5063 Positive Efficacy Results for Memory Deficits
Jul 01, 2015: Avineuro Completed Phase II Clinical Study Of AVN-211, A Selective 5-HT6 Receptor Antagonist
Dec 23, 2014: Biotie Announces Start Of Syn120 Phase 2A Trial In Parkinson's Disease Dementia And Provides Outlook Update For Near Term Pipeline Events
Dec 14, 2014: AllaChem Completes Phase Ib/IIa Clinical Study with AV4025, an HCV NS5A Inhibitor
Sep 08, 2014: Suven Life Sciences Provides Update On Its Molecule For Alzheimer's Disease
Jul 30, 2014: Biotie updates outlook on SYN120
Jul 16, 2014: Biotie Therapies Selects Bracket's CDR System for Phase 2 Trial of Treatment of Parkinson's disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Acorda Therapeutics Inc, H2 2018
Pipeline by Adamed Sp z oo, H2 2018
Pipeline by Avineuro Pharmaceuticals Inc, H2 2018
Pipeline by Celon Pharma SA, H2 2018
Pipeline by H. Lundbeck AS, H2 2018
Pipeline by Reviva Pharmaceuticals Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd..1), H2 2018
Dormant Products, H2 2018 (Contd..2), H2 2018
Dormant Products, H2 2018 (Contd..3), H2 2018
Discontinued Products, H2 2018
List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report